Latest APRE reports update at 2024-05-14: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Aprea Therapeutics APRE

$ 5.5 7.11%

Aprea Therapeutics Balance Sheet 2011-2024 | APRE

Annual Balance Sheet Aprea Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-	-130 M	-65.7 M	-24.4 M	-	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	-	256 K	242 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	303 K	113 M	56.2 M	-	-	-	-	-	-
Total Current Liabilities	4.39 M	3.2 M	7.32 M	15.3 M	9.06 M	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	15.4 M	9.36 M	117 M	60.5 M	-	-	-	-	-	-
Deferred Revenue	529 K	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-308 M	-294 M	-181 M	-144 M	-90.5 M	-62.5 M	-46.9 M	-	-	-	-	-	-
Total Assets	22.7 M	30.2 M	56.8 M	92.8 M	134 M	66 M	24.8 M	-	-	-	-	-	-
Cash and Cash Equivalents	21.6 M	28.8 M	53.1 M	89 M	130 M	65.7 M	24.4 M	-	-	-	-	-	-
Book Value	22.7 M	30.2 M	56.8 M	77.4 M	124 M	-51.4 M	-35.8 M	-	-	-	-	-	-
Total Shareholders Equity	17 M	25.6 M	49.5 M	77.4 M	124 M	-51.4 M	-35.8 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Aprea Therapeutics

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	28.1 K	-	29.8 K	-	33.8 K	78.8 K	78.8 K	78.8 K	78.8 K	303 K	303 K	303 K	303 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	3.95 M	4.23 M	3.2 M	4 M	7.68 M	6.75 M	7.32 M	9.07 M	10.6 M	11.2 M	15.4 M	15.4 M	15.4 M	15.4 M	9.36 M	9.36 M	9.36 M	9.36 M	4.87 M	4.87 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	148 K	529 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-311 M	-308 M	-305 M	-301 M	-298 M	-294 M	-291 M	-287 M	-189 M	-181 M	-173 M	-164 M	-154 M	-144 M	-144 M	-144 M	-144 M	-90.5 M	-90.5 M	-90.5 M	-90.5 M	-62.5 M	-62.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	33.2 M	22.7 M	25.8 M	28.7 M	32 M	30.2 M	33.6 M	40.7 M	50.3 M	56.8 M	62.5 M	71.5 M	80.4 M	92.8 M	92.8 M	92.8 M	92.8 M	134 M	134 M	134 M	134 M	66 M	66 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	32.4 M	21.6 M	25.4 M	27.7 M	31 M	28.8 M	33.1 M	39.1 M	47.7 M	53.1 M	61.4 M	69.8 M	77.6 M	89 M	89 M	89 M	89 M	130 M	130 M	130 M	130 M	65.7 M	65.7 M	-	-	24.4 M	-	-	-	13.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	24.7 M	27.8 M	27 M	29.6 M	33 M	43.6 M	49.5 M	53.4 M	61 M	69.1 M	77.4 M	77.4 M	77.4 M	77.4 M	124 M	124 M	124 M	124 M	61.2 M	61.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	28.9 M	17 M	20.3 M	23.4 M	26.5 M	25.6 M	26.6 M	-35.8 M	43.6 M	49.5 M	53.4 M	61 M	69.1 M	77.4 M	77.4 M	77.4 M	77.4 M	124 M	124 M	124 M	124 M	-51.4 M	-51.4 M	-44.5 M	-	-35.8 M	-	-	-	-21.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency